Ramaiah Memorial Hospital gets JCI accreditation
The hospital underwent a rigorous on-site survey conducted under JCI's 8th Edition framework, where international expert surveyors evaluated RMH for 15 chapters, 237 standards, and 1,094 measurable elements for its compliance on quality, patient safety and governance.
The hospital was recently recognised as a Comprehensive Stroke Centre by the American Stroke Association and received the Comprehensive Chest Pain Centre Certification by the American Heart Association.
'Receiving JCI accreditation is a validation of our relentless pursuit of excellence in patient care,' said M.R. Jayaram, Chairman, Gokula Education Foundation (Medical). 'JCI accreditation equips hospitals with processes that help drive improvement across various areas,' said Andrew Rosen, Vice President, Joint Commission International.
Nagendra Swamy S.C., Chief Executive – Healthcare Services, GEF (M), said the hospital is now one among the 53 Indian JCI accredited hospitals and 663 JCI accredited hospitals in the world.
The announcement was made during a special ceremony held at the hospital, attended by Union Minister Pralhad Joshi, State Health Minister Dinesh Gundu Rao and MLC M.R. Seetharam among others.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
10 minutes ago
- Business Standard
Anti-obesity drug war heats up as Wegovy and Mounjaro boost sales
India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness Sanket Koul New Delhi Listen to This Article The battle between two global majors vying for a larger pie of the Rs 628-crore Indian anti-obesity market is set to intensify, even as demand and sales for weight-loss drugs rise in a country with the third-highest number of people living with obesity. India has 254 million people with generalised obesity and 351 million with abdominal obesity, according to the Indian Council of Medical Research–INDIAB (India Diabetes) study. This segment has been in demand with the India launch of Eli Lilly's Mounjaro (tirzepatide) in March and Novo Nordisk's Wegovy (semaglutide) last month. While the former is currently priced between Rs
Mint
32 minutes ago
- Mint
Drugs regulator to turn the screws on spurious medical products
New Delhi: India's apex drug regulator—-Central Drugs Standard Control Organisation (CDSCO)—is developing a comprehensive national action plan to combat substandard and spurious medical products, officials and documents said. This follows a World Health Organization (WHO) assessment that highlighted major areas for improvement needed in India's drug regulatory framework. The proposed action plan in the works will implement new prevention, detection and response strategies at both central and state levels. A key focus will be on strengthening the surveillance and control of medical product advertisements aimed at healthcare professionals. The WHO recommended enhanced training and stricter oversight to ensure that all promotional, marketing, and advertising materials provide accurate and non-misleading information about medical products. Further, the CDSCO plans to mandate that all central and state authority websites feature a dedicated reporting page for sub-standard and falsified (spurious) products. Tighter rules for drug ads and easier reporting for public 'As part of the plan, a core component of the CDSCO's revamped approach will be the strengthening of surveillance and control over medical product advertisements, particularly those targeting healthcare professionals. Keeping a closer eye on medical product advertisements will help patients in getting accurate information, safer treatment choices, reduce the dangers of self medication, and better doctor-patient conversations. As per Indian regulations, companies cannot make advertisements of drugs following in schedule H, H1 and X. These drugs are controlled and sold in the prescription of registered medical practitioners," an official said. 'The proposal for implementation of WHO's recommendations were discussed in the Drugs Consultative Committee meeting last month chaired by the Drugs Controller General of India (DCGI). It was agreed upon to take suitable action for each of the recommendations," the official said. Tracking suprious and substandard drugs Notably, one of the important WHO's recommendations is to combat the menace of spurious and sub-standard drugs: preventing, detecting, and responding to "not of standard quality" and "spurious medical drugs," alongside a robust market surveillance program and stringent control over promotional, marketing and advertising activities. The WHO has recommended that all Central and State government websites provide a dedicated 'substandard and falsified (SF) reporting page - with information for the public on how to specifically report SF products. Reports from this mechanism should be subject to the SF report handling procedure for that organization. 'This is an important step towards increased transparency and public participation in identifying or reporting the SF products. This will empower the public to directly report suspicious products and these reports will then be properly investigated," said the official, adding that a communication from DCGI may shortly be released to all the States/UTs to implement the action points in a uniform manner. 'The government is also doing risk-based assessment of pharma firms to keep a track on the drug manufacturing and actions have also been taken," the official said. The Indian pharmaceutical market is set to reach$100 billion by 2025, as per government is the largest provider of generic drugs globally and is also known for its affordable vaccines. 'These measures will not only help protect patients but also safeguard the integrity of compliant pharmaceutical companies," said Nikkhil K. Masurkar, chief executive officer, Entod Pharmaceuticals. Masurkar said that when a spurious or falsified version of a company's drug appears in the market, it triggers significant challenges, even when the original manufacturer has followed all regulatory protocols. 'Patient safety becomes the immediate concern, but the ripple effects are far-reaching. The company can face public scepticism, reputational damage, and erosion of trust among healthcare providers, all because a counterfeit product misrepresents their brand. What makes it more difficult is that the manufacturer is often unfairly perceived as responsible, even when the fault lies entirely with external bad actors. The company is then forced to redirect time, resources, and focus towards legal action, crisis communication, and internal audits, diverting energy from innovation and patient engagement. Despite being the victim, the brand often suffers disproportionately, with long-term reputational impact that's hard to undo." Queries sent to the health ministry spokesperson and WHO remained unanswered.
&w=3840&q=100)
First Post
an hour ago
- First Post
Eli Lilly and Novo Nordisk compete in India's growing weight-loss drug market
The incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates, according to a study published in the medical journal The Lancet read more Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday. Lilly's Mounjaro, launched in late March, doubled its sales in June to 87,986 units or 260 million rupees ($3.03 million) compared to May, Pharmarack said. Between March and May, Lilly had sold 81,570 Mounjaro units in India. Meanwhile, Novo sold 1,788 units of Wegovy in India since its late-June launch with 25.3 million rupees in sales, Pharmarack said. STORY CONTINUES BELOW THIS AD The incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates, according to a study published in the medical journal The Lancet. The Indian obesity drug market has grown fivefold since 2021 and is valued at 6.28 billion rupees, according to the research firm. Affordability and willingness to try new drugs for obesity have propelled the growth of the market, Pharmarack's Vice President (Commercial) Sheetal Sapale said. Wegovy's active ingredient, semaglutide, dominates the market with a two-thirds share in India, while Mounjaro's active ingredient, tirzepatide, has captured 8% of the market, Pharmarack said. As of June, the semaglutide market in India was valued at 4.12 billion rupees, and tirzepatide at 500 million rupees, the research firm said. Novo has sold oral versions of semaglutide for diabetes in India since 2022. Semaglutide will lose patent protection in India in 2026, and generic drugmakers are aiming to produce cheaper versions of Wegovy as India becomes a key battleground for drugmakers seeking to grab a share of the global obesity market. Novo and Lilly's drugs help control blood sugar and slow digestion, making users feel fuller for longer. STORY CONTINUES BELOW THIS AD ($1 = 85.9200 Indian rupees)
